EPT0505
EPN · EPN Tumor
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- EPN Tumor
- cancer_type
- EPN
- subtype
- EPN Tumor
- e1_e2
- E2
- umap1_2d
- -7.148203767
- umap2_2d
- 0.663486875
- umap1_3d
- 1.198943238
- umap2_3d
- 3.811361658
- umap3_3d
- 0.889674944
- dataset
- EPN-Toronto
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.570
- INTERFERON_GAMMA_RESPONSE+0.400
- ALLOGRAFT_REJECTION+0.350
- OXIDATIVE_PHOSPHORYLATION+0.320
- BILE_ACID_METABOLISM+0.310
- MYOGENESIS+0.200
- P53_PATHWAY+0.180
- PANCREAS_BETA_CELLS+0.170
- KRAS_SIGNALING_DN+0.160
- IL6_JAK_STAT3_SIGNALING+0.150
Top 10 suppressed
- ANGIOGENESIS-0.530
- G2M_CHECKPOINT-0.500
- E2F_TARGETS-0.460
- MITOTIC_SPINDLE-0.400
- MYC_TARGETS_V2-0.380
- WNT_BETA_CATENIN_SIGNALING-0.360
- MTORC1_SIGNALING-0.290
- UV_RESPONSE_DN-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.270
- TGF_BETA_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-6597-01A-11R-1858-07 | — | cohortA1 | 0.872 |
| 2 | ERR2598330 | fetal | fetal | 0.864 |
| 3 | ERR2598320 | fetal | fetal | 0.836 |
| 4 | TCGA-BA-A6DB-01A-11R-A30B-07 | — | — | 0.832 |
| 5 | MDT-AP-0377 | Med | Medulloblastoma | 0.828 |
| 6 | X3cd3fbb2.8eb1.4fd0.ae5f.c940ae00e311 | — | cohortA1 | 0.825 |
| 7 | TCGA-44-2661-01A-01R-1107-07 | — | cohortA1 | 0.822 |
| 8 | 28f73ee0-f218-4884-81c6-e6b4ba2fdccd | — | — | 0.820 |
| 9 | ERR2598271 | fetal | fetal | 0.819 |
| 10 | TCGA-CV-A461-01A-41R-A266-07 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.110 | Idelalisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.050 | Idelalisib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |